Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Sep 5, 2023
Discovery & Translation
Epitope editing of immunotherapies; plus NovoBiotic’s antibiotic and more
BioCentury’s roundup of translational innovations
BioCentury | May 10, 2023
Deals
How CTI found its target population and set itself up for a $1.7B takeout by Sobi
Swedish company pays 89% premium to add Vonjo to hematology portfolio, a year after its accelerated approval in a disease space dominated by Jakafi
BioCentury | Apr 21, 2023
Regulation
April 21 Quick Takes: LianBio’s mavacamten gets priority review in China
Plus: FDA extends PDUFA for Daiichi’s quizartinib, and updates from AbbVie, Apellis and more
BioCentury | Mar 31, 2023
Data Byte
At least 11 PDUFA dates on deck in April
FDA decisions due next month include tofersen, SER-109, quizartinib and aripiprazole
BioCentury | Feb 7, 2023
Management Tracks
Astellas shuffles top management amid push to reshape strategically
As pharma implements growth plan to look beyond Xtandi, rising CEO Okamura figures to execute on launches, develop in newer modalities
BioCentury | Dec 20, 2022
Product Development
Stem cell transplants aim for next level of sophistication
Gene editing stem cell transplants makes targeted myeloid, T cell cancer therapies safer: ASH 2022
BioCentury | Dec 8, 2022
Discovery & Translation
AML gains new targets at ASH 2022
BioCentury identifies 29 novel drug targets at ASH 2022; 15 are proposed for AML
BioCentury | May 20, 2022
Discovery & Translation
Precision’s chronic HBV gene therapy; plus Blaze and ASGCT highlights
BioCentury’s roundup of translational news
BioCentury | May 12, 2022
Deals
Cullinan gets $275M up front, reshapes deal with Taiho for EGFR program
Three years after sourcing targeted cancer program from Japanese pharma, Cullinan sells back subsidiary while retaining upside
BioCentury | Mar 12, 2022
Discovery & Translation
Translational highlights to watch for at AACR
BioCentury’s roundup of translational abstracts ahead of the 2022 American Association for Cancer Research conference
Items per page:
1 - 10 of 254